Trial Profile
Evaluation of the Activity of Temsirolimus With FDG-PET and FLT-PET in Patients With Renal Cell Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 15 Sep 2011 New trial record